Holen Sie sich die Stockscreener-App
52.92
0.79%
-0.42
Handel nachbörslich:
52.92
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Forum
Prognose
Aktiensplit
Dividendenhistorie
Schlusskurs vom Vortag:
$53.34
Offen:
$53.19
24-Stunden-Volumen:
2.40M
Relative Volume:
1.05
Marktkapitalisierung:
$8.23B
Einnahmen:
$1.17B
Nettoeinkommen (Verlust:
$150.71M
KGV:
56.30
EPS:
0.94
Netto-Cashflow:
$245.03M
1W Leistung:
-2.60%
1M Leistung:
-3.57%
6M Leistung:
-11.98%
1J Leistung:
-25.59%
1-Tages-Spanne:
$51.62
$53.19
1-Wochen-Bereich:
$51.62
$55.25
52-Wochen-Spanne:
$46.01
$80.95
Bio Techne Corp Stock (TECH) Company Profile
Firmenname
Bio Techne Corp
Sektor
Branche
Telefon
(612) 379-8854
Adresse
614 MCKINLEY PL N E, MINNEAPOLIS, MN
Vergleichen Sie TECH mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
TECH
Bio Techne Corp
|
52.92 | 8.31B | 1.17B | 150.71M | 245.03M | 0.94 |
|
VRTX
Vertex Pharmaceuticals Inc
|
396.93 | 102.81B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
453.54 | 58.59B | 2.46B | -319.09M | -52.09M | -2.47 |
|
REGN
Regeneron Pharmaceuticals Inc
|
567.22 | 61.25B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ARGX
Argen X Se Adr
|
733.66 | 43.23B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
318.73 | 36.53B | 3.81B | -644.79M | -669.77M | -6.24 |
Bio Techne Corp Stock (TECH) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-08-21 | Hochstufung | Citigroup | Neutral → Buy |
| 2025-07-22 | Fortgesetzt | Stephens | Overweight |
| 2025-07-09 | Eingeleitet | TD Cowen | Buy |
| 2025-05-30 | Eingeleitet | Wells Fargo | Overweight |
| 2025-04-09 | Herabstufung | KeyBanc Capital Markets | Overweight → Sector Weight |
| 2025-03-18 | Eingeleitet | Evercore ISI | Outperform |
| 2025-02-19 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2024-05-22 | Herabstufung | Citigroup | Buy → Neutral |
| 2024-02-08 | Eingeleitet | Scotiabank | Sector Outperform |
| 2024-02-02 | Herabstufung | Stifel | Buy → Hold |
| 2023-12-07 | Eingeleitet | UBS | Buy |
| 2023-08-28 | Eingeleitet | William Blair | Outperform |
| 2023-01-10 | Hochstufung | Wells Fargo | Underweight → Equal Weight |
| 2022-12-14 | Eingeleitet | Deutsche Bank | Buy |
| 2022-12-12 | Hochstufung | Citigroup | Neutral → Buy |
| 2022-12-07 | Eingeleitet | RBC Capital Mkts | Sector Perform |
| 2022-08-25 | Eingeleitet | Credit Suisse | Outperform |
| 2022-04-25 | Herabstufung | Wells Fargo | Equal Weight → Underweight |
| 2021-09-15 | Hochstufung | KeyBanc Capital Markets | Sector Weight → Overweight |
| 2021-03-08 | Hochstufung | Stephens | Equal-Weight → Overweight |
| 2021-02-23 | Hochstufung | Stifel | Hold → Buy |
| 2021-01-25 | Bestätigt | The Benchmark Company | Buy |
| 2020-11-10 | Eingeleitet | KeyBanc Capital Markets | Sector Weight |
| 2020-09-30 | Eingeleitet | Atlantic Equities | Overweight |
| 2020-07-15 | Herabstufung | Stephens | Overweight → Equal-Weight |
| 2020-05-27 | Herabstufung | Stifel | Buy → Hold |
| 2020-05-14 | Eingeleitet | The Benchmark Company | Buy |
| 2020-01-08 | Fortgesetzt | Stephens | Overweight |
| 2020-01-08 | Eingeleitet | Wells Fargo | Equal Weight |
| 2020-01-07 | Eingeleitet | Citigroup | Neutral |
| 2019-11-15 | Eingeleitet | Stifel | Buy |
| 2019-07-02 | Hochstufung | Janney | Neutral → Buy |
| 2019-01-14 | Hochstufung | Stephens | Equal-Weight → Overweight |
| 2018-10-31 | Herabstufung | Craig Hallum | Buy → Hold |
| 2018-10-17 | Eingeleitet | Goldman | Neutral |
| 2018-06-15 | Eingeleitet | Argus | Buy |
| 2017-07-13 | Eingeleitet | Wells Fargo | Market Perform |
| 2017-02-09 | Eingeleitet | Citigroup | Buy |
| 2017-01-18 | Eingeleitet | Deutsche Bank | Buy |
| 2016-11-10 | Fortgesetzt | Leerink Partners | Outperform |
| 2015-01-21 | Bestätigt | Robert W. Baird | Outperform |
| 2013-09-20 | Hochstufung | Robert W. Baird | Neutral → Outperform |
Alle ansehen
Bio Techne Corp Aktie (TECH) Neueste Nachrichten
Can Bio Techne Corporation benefit from deglobalizationWeekly Profit Summary & Stock Portfolio Risk Control - khodrobank.com
Bio-Techne at Wells Fargo: Navigating Growth Amid Tariff Concerns - Investing.com
Bio-Techne Stock Upgraded As Analyst Flags Attractive Entry PointBio-Techne (NASDAQ:TECH) - Benzinga
Bio-Techne Corp. Stock Underperforms Tuesday When Compared To Competitors - 富途牛牛
Market reaction to Bio Techne Corporation’s recent newsTrade Performance Summary & Stepwise Entry/Exit Trade Alerts - Newser
Quantitative breakdown of Bio Techne Corporation recent move2025 Earnings Surprises & Safe Swing Trade Setup Alerts - Newser
Candlestick signals on Bio Techne Corporation stock todayMarket Performance Recap & Capital Efficiency Focused Ideas - Newser
Using portfolio simulators with Bio Techne Corporation includedWeekly Risk Report & Capital Efficiency Focused Strategies - Newser
Is Bio Techne Corporation a candidate for recovery playInsider Selling & Precise Buy Zone Tips - Newser
Is Bio Techne Corporation still worth holding after the dip2025 Trade Ideas & Weekly Hot Stock Watchlists - Newser
Is Bio Techne Corporation stock a good dividend stock2025 Winners & Losers & Daily Stock Trend Watchlist - khodrobank.com
Why Bio-Techne (TECH) Shares Are Sliding Today - Yahoo Finance
Bio-Techne Corp. stock underperforms Thursday when compared to competitors - MSN
How high can Bio Techne Corporation stock goMarket Growth Summary & Scalable Portfolio Growth Methods - Newser
What earnings revisions data tells us about Bio Techne CorporationQuarterly Market Summary & Community Consensus Trade Alerts - Newser
Bio Techne Corporation stock outlook for YEARWeekly Loss Report & Weekly High Return Forecasts - Newser
Applying chart zones and confluence areas to Bio Techne CorporationJuly 2025 Analyst Calls & High Accuracy Trade Alerts - Newser
How to interpret RSI for Bio Techne Corporation stock2025 EndofYear Setup & Verified Trade Idea Suggestions - Newser
Can Bio Techne Corporation outperform in the next rallyJuly 2025 Recap & Weekly Momentum Picks - khodrobank.com
Is it time to cut losses on Bio Techne CorporationJuly 2025 Macro Moves & Low Risk High Win Rate Stock Picks - Newser
Published on: 2025-09-01 12:30:20 - Newser
Using Ichimoku Cloud for Bio Techne Corporation technicalsJuly 2025 Selloffs & Precise Swing Trade Alerts - Newser
What machine learning models say about Bio Techne CorporationBear Alert & Community Consensus Picks - Newser
Chart based exit strategy for Bio Techne CorporationPortfolio Return Report & Weekly High Conviction Trade Ideas - Newser
Automated trading signals detected on Bio Techne CorporationMarket Activity Report & Consistent Profit Trading Strategies - Newser
Published on: 2025-08-30 21:11:50 - Newser
Applying big data sentiment scoring on Bio Techne Corporation2025 Volume Leaders & Weekly Momentum Picks - Newser
Using economic indicators to assess Bio Techne Corporation potentialQuarterly Profit Summary & Weekly High Return Forecasts - Newser
Real time alert setup for Bio Techne Corporation performance2025 Key Lessons & Breakout Confirmation Alerts - Newser
Fibonacci Retracement Aligns with Support in Bio Techne Corporation getLinesFromResByArray error: size == 0 - 클래시안
Tools to monitor Bio Techne Corporation recovery probabilityJuly 2025 Outlook & Weekly Return Optimization Alerts - Newser
Published on: 2025-08-28 20:41:13 - Newser
Using Python tools to backtest Bio Techne Corporation strategiesEntry Point & Long-Term Safe Return Strategies - Newser
Bio-Techne Corp to Present at Several Upcoming Investor Conferences - AInvest
BIO-TECHNE Corp Directors Execute Share Sales - TradingView
Finanzdaten der Bio Techne Corp-Aktie (TECH)
Umsatz
Nettogewinn
Free Cashflow
ENV
Bio Techne Corp-Aktie (TECH) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Nusse Roeland | Director |
Aug 25 '25 |
Sale |
56.36 |
17,040 |
960,388 |
44,559 |
| BAUMGARTNER ROBERT V | Director |
Aug 25 '25 |
Option Exercise |
21.84 |
17,040 |
372,154 |
61,903 |
| BAUMGARTNER ROBERT V | Director |
Aug 25 '25 |
Sale |
56.21 |
17,040 |
957,818 |
44,863 |
1.75%
1.11%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):